Events

Back
img

Immune Checkpoint Inhibitors Boston

Conference

Start Time:15 Mar 2016, 9:00 AM

End Time:17 Mar 2016, 5:00 PM

Where:Revere Hotel Boston Common, 200 Stuart Street, Boston, United States

As the frenzy of preclinical and clinical programs continues, it is critical to take a step back and work out what is working and what is not. At this year's ICI Boston we are gathering the field's experts to review the latest research and clinical success of checkpoint modulators.

With insights and fresh data from early validation through to clinical strategy we've curated the most valuable and important case studies from the last 12 months.

Working with the likes of BMS, Merck, AstraZeneca and EMD Serono to understand the biggest challenges in checkpoint inhibition; the agenda is designed to cut through the hype and share real insights and how the industry's best are effectively progressing their pipelines through the clinic and onto the market.

ICI Boston will help you leverage the new understanding of pathway biology and biomarker strategy in the development of your checkpoint drugs. Listen to data and experiences from 31 experts in immune checkpoint regulation as they share what has speed their programs to success so far.

Focusing on the translational challenges that drug developers face in bringing these therapies there will be information shared on the most pressing industry challenges:

-Hear about discovery and validation of pathway biologies beyond PD-1
-Review immuno-oncology combinations that deliver more robust and durable patient responses
-Learn aboutnovel biomarkers for patient stratification
-Appreciate the commercial strategy of the most advanced players and assess market opportunities for the year to come

URLs:
Booking: http://atnd.it/42080-1
Tickets: http://atnd.it/42080-2

Prices:
Platinum: Conference + 3 workshops: USD 4496,
Gold: Conference + 2 workshops: USD 3897,
Silver: Conference + 1 workshop: USD 3298,
Bronze: Conference only : USD 2699,
Workshops: USD 699

Speakers: Gary Bembridge, Director - Scientific Affairs, Immunology, Abenza, Jon Wigginton, SVP-Clinical Development, MacroGenics, Axel Hoos, VP - Oncology RandD, GSK, Mary Lynne Hedley, President and COO, TESARO, Naiyer Rizvi, Director of Immunotherapeutics, Columbia University Medical Center, Paul Rennert, Founder and Principal, SugarCone Biotech Consultants, Jennifer Wargo, Associate Professor MD Anderson Cancer Centre, Chris Turner, VP – Clinical Science, Celldex, Jonathon Sedgwick, Global Head – Immune Modulation, Boehringer Ingelheim, Eric Rubin, VP – Global Clinical Oncology, Merck, Patrick Ott, Clinical Director, Centre for Immuno-Oncology, Dana-Farber, Ruslan Novosiadly, Senior Research Advisor - Biomarkers, Eli Lilly, Walter Newman, Director, GITR Inc., Jason Luke, Assistant Professor, University of Chicago, Holly Koblish, Associate Director, Incyte, Francis Kern, Senior Director – External Scientific Affairs, Daiichi Sankyo, David Kaufman, Executive Director – Translational Immuno-Oncology, Merck, Jeff Hutchins, VP – Preclinical Research, Peregrine Pharmaceuticals, Tony Ho, Global Medicine Leader Durvalumab (MEDI4736), AstraZeneca, Fiona Harding, Senior Principal Research Scientist, Abbvie, Bill Grossman, Group Medical Director – Cancer Immunotherapy Franchise, Genentech, Philip Gotwals, Executive Director, Exploratory Immuno-Oncology, Novartis, Michael Giordano, SVP, Head of Immuno-Oncology Development, Bristol-Myers Squibb, Roy Baynes, SVP, Global Clinical Development, Merck, Tehila Ben-Moshe, CEO, VP – RandD cCAM Biotherapeutics, Jean-Marie Cuillerot, VP – Development Immuno-Oncology, EMD Serono, Greg Dombal, COO, Halloran Consulting Group, Andrew Ferguson, Clinical Scientist, TESARO, Tara Gangadhar, Assistant Professor, Abramson Cancer Center, University of Pennsylvania

Organizers:
Jenny Barlow, Hanson Wade Ltd, London, United Kingdom.

Back

You are in

Cancer Drug Development

View All Events
RSVP